Island Pharmaceuticals Enters Agreement to Advance Galidesivir Approval, Shares Up 19%

MT Newswires Live

03/04

Island Pharmaceuticals (ASX:ILA) said it has entered into a cooperative research and development agreement with the US Army Medical Research Institute of Infectious Diseases and The Geneva Foundation to accelerate Animal Rule approval for Galidesivir, according to a Wednesday Australian bourse filing.

The company said the agreement is aimed at advancing Galidesivir under the US Food and Drug Administration's Animal Rule development pathway for the treatment of Marburg Virus Disease.

Galidesivir is a clinical-stage antiviral molecule with broad-spectrum activity against over 20 RNA viruses, including Ebola, Marburg, MERS, Zika, and Yellow fever, the filing added.

The company's shares were up 19% in recent Wednesday trade.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2616905308"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2616905308\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2616905308?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-04 07:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2616905308","market":"nz","top_or_hot":-1,"title":"Island Pharmaceuticals Enters Agreement to Advance Galidesivir Approval, Shares Up 19%","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/ILA.AU\">Island Pharmaceuticals</a> (ASX:ILA) said it has entered into a cooperative research and development agreement with the US Army Medical Research Institute of Infectious Diseases and The Geneva Foundation to accelerate Animal Rule approval for Galidesivir, according to a Wednesday Australian bourse filing.</p><p>The company said the agreement is aimed at advancing Galidesivir under the US Food and Drug Administration's Animal Rule development pathway for the treatment of Marburg Virus Disease.</p><p>Galidesivir is a clinical-stage antiviral molecule with broad-spectrum activity against over 20 RNA viruses, including Ebola, Marburg, MERS, Zika, and Yellow fever, the filing added.</p><p>The company's shares were up 19% in recent Wednesday trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Island Pharmaceuticals Enters Agreement to Advance Galidesivir Approval, Shares Up 19%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIsland Pharmaceuticals Enters Agreement to Advance Galidesivir Approval, Shares Up 19%\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-03-04 07:36</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/ILA.AU\">Island Pharmaceuticals</a> (ASX:ILA) said it has entered into a cooperative research and development agreement with the US Army Medical Research Institute of Infectious Diseases and The Geneva Foundation to accelerate Animal Rule approval for Galidesivir, according to a Wednesday Australian bourse filing.</p><p>The company said the agreement is aimed at advancing Galidesivir under the US Food and Drug Administration's Animal Rule development pathway for the treatment of Marburg Virus Disease.</p><p>Galidesivir is a clinical-stage antiviral molecule with broad-spectrum activity against over 20 RNA viruses, including Ebola, Marburg, MERS, Zika, and Yellow fever, the filing added.</p><p>The company's shares were up 19% in recent Wednesday trade.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ILA.AU","symbol_name":"ISLAND PHARMACEUTICALS LTD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2616905308","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2616905308","pubTimestamp":1772581001,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Island Pharmaceuticals (ASX:ILA) said it has entered into a cooperative research and development agreement with the US Army Medical Research Institute of Infectious Diseases and The Geneva Foundation ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ILA.AU":"ISLAND PHARMACEUTICALS LTD","BK7096":"制药"},"translate_title":"Island Pharmaceuticals达成协议推进加利德西韦审批，股价上涨19%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ILA.AU":1},"content_text":"Island Pharmaceuticals (ASX:ILA) said it has entered into a cooperative research and development agreement with the US Army Medical Research Institute of Infectious Diseases and The Geneva Foundation to accelerate Animal Rule approval for Galidesivir, according to a Wednesday Australian bourse filing.The company said the agreement is aimed at advancing Galidesivir under the US Food and Drug Administration's Animal Rule development pathway for the treatment of Marburg Virus Disease.Galidesivir is a clinical-stage antiviral molecule with broad-spectrum activity against over 20 RNA viruses, including Ebola, Marburg, MERS, Zika, and Yellow fever, the filing added.The company's shares were up 19% in recent Wednesday trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}